Skip to main content
Bhanvi Satija on Muck Rack

Bhanvi Satija

Verified
  • European Pharmaceuticals Correspondent, Reuters
New Delhi
As seen in: Reuters, MSN, MSN Canada, MSN Ireland, MSN Money Canada, MSN Singapore, MSN UK, UOL, ET Healthworld, MSN South Africa, Reuters Japan and
Covering U.S. Health and Pharma for Reuters. Views expressed are my own. RTs ≠ endorsements. Sporadic Twitter-er.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bhanvi

Contact Bhanvi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Novartis faces drug pipeline test with valuation premium in focus

|
By Bhanvi Satija Verified
| MSN Verified
Bhanvi Satija By Bhanvi Satija LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation.
Open in Who Shared View Duplicates (6) Issue with article?

Novartis faces drug pipeline test with valuation premium in focus

|
By Bhanvi Satija Verified
| KDAL-FM (Duluth , MN) Verified
By Bhanvi Satija LONDON, July 20 (Reuters) – Novartis investors will look beyond Tuesday’s quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker’s premium valuation.
Open in Who Shared View Duplicates (98) Issue with article?
See all 8,921 licensed articles (9,166 Total)